First Light Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-185,579
| Closed | -$17.9M | – | 54 |
|
|
2023
Q4 | $17.9M | Buy |
185,579
+123,823
| +201% | +$11M | 1.44% | 24 |
|
|
2023
Q3 | $5.46M | Buy |
61,756
+1,102
| +2% | +$98.1K | 0.52% | 39 |
|
|
2023
Q2 | $5.26M | Sell |
60,654
-828
| -1% | -$77.9K | 0.41% | 42 |
|
|
2023
Q1 | $5.98M | Sell |
61,482
-59,459
| -49% | -$6.16M | 0.54% | 37 |
|
|
2022
Q4 | $12.5M | Sell |
120,941
-2,381
| -2% | -$224K | 1.16% | 29 |
|
|
2022
Q3 | $10.5M | Buy |
123,322
+18,509
| +18% | +$1.65M | 1.06% | 30 |
|
|
2022
Q2 | $8.69M | Buy |
104,813
+11,731
| +13% | +$934K | 1.01% | 32 |
|
|
2022
Q1 | $7.18M | Sell |
93,082
-34,703
| -27% | -$2.9M | 0.63% | 36 |
|
|
2021
Q4 | $11.3M | Sell |
127,785
-48,774
| -28% | -$4.02M | 0.81% | 35 |
|
|
2021
Q3 | $13.6M | Buy |
+176,559
| New | +$13.9M | 0.9% | 36 |
|
|
2020
Q3 | – | Sell |
-103,310
| Closed | -$12.7M | – | 62 |
|
|
2020
Q2 | $12.7M | Sell |
103,310
-1,847
| -2% | -$184K | 1.48% | 26 |
|
|
2020
Q1 | $8.89M | Buy |
105,157
+3,647
| +4% | +$314K | 1.52% | 23 |
|
|
2019
Q4 | $8.58M | Sell |
101,510
-2,042
| -2% | -$154K | 1.1% | 26 |
|
|
2019
Q3 | $6.98M | Buy |
103,552
+33,475
| +48% | +$2.58M | 1.06% | 28 |
|
|
2019
Q2 | $6M | Buy |
70,077
+4,417
| +7% | +$378K | 0.83% | 35 |
|
|
2019
Q1 | $5.83M | Buy |
65,660
+3,821
| +6% | +$354K | 0.76% | 33 |
|
|
2018
Q4 | $5.27M | Sell |
61,839
-459
| -0.7% | -$43.7K | 0.84% | 27 |
|
|
2018
Q3 | $6.04M | Sell |
62,298
-452
| -0.7% | -$45.1K | 0.97% | 24 |
|
|
2018
Q2 | $5.91M | Buy |
62,750
+30,900
| +97% | +$2.71M | 0.92% | 26 |
|
|
2018
Q1 | $2.58M | Buy |
31,850
+637
| +2% | +$54.7K | 0.57% | 34 |
|
|
2017
Q4 | $2.78M | Sell |
31,213
-689
| -2% | -$59.9K | 0.76% | 32 |
|
|
2017
Q3 | $2.97M | Buy |
31,902
+335
| +1% | +$29.6K | 0.94% | 30 |
|
|
2017
Q2 | $2.87M | Sell |
31,567
-25
| -0.1% | -$2.27K | 0.96% | 32 |
|
|
2017
Q1 | $2.77M | Sell |
31,592
-167
| -0.5% | -$14.9K | 1.06% | 30 |
|
|
2016
Q4 | $2.63M | Sell |
31,759
-153
| -0.5% | -$13.2K | 1.16% | 29 |
|
|
2016
Q3 | $2.95M | Buy |
31,912
+13,397
| +72% | +$1.26M | 1.27% | 33 |
|
|
2016
Q2 | $1.44M | Sell |
18,515
-340
| -2% | -$28.9K | 0.67% | 41 |
|
|
2016
Q1 | $1.55M | Sell |
18,855
-46
| -0.2% | -$3.74K | 0.78% | 39 |
|
|
2015
Q4 | $1.98M | Sell |
18,901
-252
| -1% | -$26.3K | 0.83% | 41 |
|
|
2015
Q3 | $2.02M | Buy |
19,153
+2,788
| +17% | +$372K | 1% | 34 |
|
|
2015
Q2 | $2.24M | Sell |
16,365
-8,241
| -33% | -$1.02M | 1.05% | 32 |
|
|
2015
Q1 | $3.07M | Buy |
24,606
+2,544
| +12% | +$270K | 1.57% | 26 |
|
|
2014
Q4 | $1.99M | Buy |
22,062
+1,737
| +9% | +$144K | 1.13% | 33 |
|
|
2014
Q3 | $1.47M | Buy |
20,325
+573
| +3% | +$37.7K | 1% | 35 |
|
|
2014
Q2 | $1.23M | Buy |
19,752
+1,063
| +6% | +$64.2K | 0.83% | 39 |
|
|
2014
Q1 | $1.27M | Buy |
18,689
+2,472
| +15% | +$182K | 0.9% | 35 |
|
|
2013
Q4 | $1.14M | Buy |
+16,217
| New | +$1.1M | 0.97% | 32 |
|
Other funds holding BMRN
First Light Asset Management's BMRN Position: Q1 2024 in Review
First Light Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 185,579 shares — an estimated $17.9M sold.
First Light Asset Management first reported a position in BMRN in Q4 2013 and held it in 37 quarters. The position peaked at $17.9M in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.
- First Light Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
- First Light Asset Management sold 185,579 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $17.9M.
- First Light Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 37 quarters.
- First Light Asset Management's BioMarin Pharmaceuticals position peaked at $17.9M in Q4 2023.
- 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.
Based on First Light Asset Management's 13F filing for Q1 2024, filed 15 May 2024.